Investors Can Lead Class Action Against Soleno Therapeutics for Securities Fraud

Investors Given Opportunity to Lead Soleno Therapeutics Class Action

In a significant turn of events, investors holding securities of Soleno Therapeutics, Inc. are now presented with the chance to take the lead in a class action lawsuit against the company, facilitated by the Schall Law Firm. This lawsuit centers on allegations that Soleno has committed securities fraud, raising serious concerns among investors who purchased shares during a specified period.

The Schall Law Firm, recognized nationally for its shareholder rights litigation, is reminding everyone that those who bought Soleno's securities between March 26, 2025, and November 4, 2025, have until May 5, 2026, to make their voices heard. If you have experienced financial losses associated with your investment in Soleno, this is a crucial opportunity for you to participate.

The lawsuit, premised on violations of the Securities Exchange Act of 1934, specifically focuses on Sections 10(b) and 20(a), alongside Rule 10b-5 instituted by the U.S. Securities and Exchange Commission. The crux of the allegations asserts that Soleno made false and misleading statements pertaining to the safety and commercial viability of its treatment, diazoxide choline extended-release tablets (DCCR).

According to the Complaint, Soleno has downplayed serious safety concerns that were revealed during its Phase 3 clinical trial of DCCR. The company reportedly misrepresented the severity of potential risks associated with this treatment, leading investors to believe in a far more reliable product than was actually the case. Details emerging from these trials suggested increased safety hazards that were not adequately communicated to the market, misleading investors about the treatment’s viability and potential adverse effects.

The Schall Law Firm has currently not certified the class, which means that those who do not take action might miss out on representation within this legal process. Therefore, it's imperative for affected shareholders to reach out to the Schall Law Firm if they wish to actively participate.

Investors looking to discuss their rights regarding this lawsuit are encouraged to contact Brian Schall at the Schall Law Firm. This outreach is beneficial, as he can provide insights and a free consultation regarding the next steps. The firm's office contact number is 310-301-3335, and more information can be found on their official website, www.schallfirm.com.

By joining this class action lawsuit, investors can strengthen their position against perceived wrongdoing by Soleno Therapeutics, potentially easing the financial burden they may have suffered as a result of the company's alleged actions.

In conclusion, this lawsuit marks a pivotal moment for investors seeking justice in light of alleged securities fraud. The Schall Law Firm’s commitment to representing shareholder rights is commendable, and affected investors should seize this opportunity to recover losses related to their investments in Soleno Therapeutics.